FDA Labeling, NDCs, Recalls and REMS Explained
Educational only, not medical advice. This guide explains general US pharmacy-technician topics. Follow your training, your pharmacist, your state board and the official references for real patients.
The DEA governs controlled substances, but almost every product on a pharmacy shelf is shaped by the Food and Drug Administration (FDA). FDA decides whether a drug needs a prescription, what its label must say, how it is identified, and what happens when something goes wrong. This guide covers the FDA topics that show up most in pharmacy technician work and on the certification exam.
The FDCA and Rx vs OTC labeling
The Federal Food, Drug, and Cosmetic Act (FDCA) is the main federal drug law, and FDA enforces it. Two words from the Act come up constantly:
- Adulterated: something is wrong with the product itself, such as contamination or poor manufacturing.
- Misbranded: something is wrong with the labeling, such as false or missing information.
Two amendments matter for pharmacy:
- The Durham-Humphrey Amendment (1951) created the legal line between prescription and over-the-counter drugs (section 503(b) of the Act).
- The FDA Modernization Act of 1997 requires a prescription drug label to carry, at a minimum, the symbol "Rx only."
Prescription vs OTC
A prescription (legend) drug is one that is not safe to use except under a licensed prescriber's supervision. Its manufacturer label carries "Rx only," and the prescribing information is written for health professionals.
An OTC drug is labeled for consumers to use on their own. Its label uses the standardized Drug Facts panel, with headings in a set order:
- Active ingredient(s), with the amount per dosage unit
- Purpose(s)
- Use(s)
- Warnings
- Directions
- Other information (such as storage)
- Inactive ingredients
Because the order never changes, patients can find warnings and directions in the same place on every product.
Reading an NDC
Every drug listed with FDA has a National Drug Code (NDC): today a 10-digit number in three segments.
- Labeler code: assigned by FDA; identifies the firm.
- Product code: assigned by the firm; identifies strength, dosage form and formulation.
- Package code: assigned by the firm; identifies package size and type.
The 10 digits come in three configurations: 4-4-2, 5-3-2 or 5-4-1. Billing systems commonly use an 11-digit 5-4-2 version, made by adding a leading zero to whichever segment is short.
Worked examples (made-up numbers):
| 10-digit NDC | Configuration | 11-digit (5-4-2) |
|---|---|---|
| 1234-5678-90 | 4-4-2 | 01234-5678-90 |
| 12345-678-90 | 5-3-2 | 12345-0678-90 |
| 12345-6789-0 | 5-4-1 | 12345-6789-00 |
In each case exactly one zero is added, so 10 digits become 11.
FDA has issued a final rule (published March 5, 2026) that moves all FDA-assigned NDCs to a single 12-digit 6-4-2 format: a 6-digit labeler code, a 4-digit product code and a 2-digit package code. The rule takes effect on March 7, 2033, and until then FDA keeps assigning 10-digit NDCs. On that date, FDA starts assigning 12-digit NDCs and converts every existing 10-digit NDC by adding leading zeros to segments as needed; for example, 12345-678-90 becomes 012345-0678-90 (one zero added to the labeler code and one to the product code, so 10 + 2 = 12 digits). A converted code is the same NDC in a new format, not a new NDC. A three-year transition period follows (March 7, 2033 to March 6, 2036), during which FDA does not intend to object to 10-digit NDCs still printed on drug labels. The rule does not itself change the 11-digit billing format, but FDA expects billing standards to be updated to handle 12-digit NDCs.
Medication Guides and REMS
Medication Guides
A Medication Guide is an FDA-approved patient handout for certain prescription drugs that FDA has decided pose a serious and significant public health concern (21 CFR Part 208). Key points for the pharmacy:
- The dispenser must give the Medication Guide to the patient, or the patient's agent, when the drug is dispensed.
- The container label tells the dispenser that a Guide must be provided.
- Even if a prescriber decides a patient should not get one, the pharmacy must still provide it if the patient asks.
REMS
A Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program FDA can require for a medication with a serious risk, authorized by the FDA Amendments Act of 2007. A REMS may include:
- a Medication Guide
- a communication plan for health care providers
- Elements to Assure Safe Use (ETASU)
- an implementation system
ETASU are the strictest tools. They can require certified prescribers, certified pharmacies, documented safe-use conditions such as lab results or pregnancy testing, and patient enrollment. Two examples with ETASU:
- Isotretinoin (iPLEDGE REMS): only specially certified pharmacies may dispense, and the pharmacy must obtain an authorization before dispensing.
- Thalidomide REMS: prescribers and dispensing pharmacies must be specially certified, and pharmacies complete training before dispensing.
When a brand-name drug has a REMS, its generic versions must have one too. Sometimes the brand and generic makers run one joint "shared system" REMS (iPLEDGE, which covers all isotretinoin products, is an example); other times each has its own REMS with the same goals and requirements. Not every REMS includes ETASU: some rely only on a Medication Guide or on communications to health care providers.
Recalls and MedWatch reporting
Recall classes
Most recalls are carried out by the manufacturer or distributor, and FDA classifies them by health risk:
- Class I: a reasonable probability that using the product will cause serious adverse health consequences or death. Most serious.
- Class II: use may cause temporary or medically reversible health problems, or the chance of serious harm is remote.
- Class III: use is not likely to cause harm, but the product breaks FDA rules, such as a minor labeling error.
A market withdrawal is not a recall: the firm removes or corrects a product that has only a minor violation FDA would not take legal action over, or no violation at all (for example, a product pulled after tampering with no sign of a manufacturing or distribution problem).
Each recall also states how far down the supply chain it reaches: wholesale, retail or consumer level. A technician's usual job is to check the recall notice against lot numbers on the shelf, pull and quarantine matching stock, and follow the return instructions.
MedWatch
MedWatch is FDA's safety information and adverse event reporting program.
- Form 3500: voluntary reports from health professionals of adverse events, medication errors and product quality problems.
- Form 3500B: a plain-language voluntary form for patients and consumers.
- Form 3500A: mandatory reporting by manufacturers, distributors, importers, IND reporters and user facilities; FDA says these reports must be submitted electronically.
Reports can be filed online. Medication errors can also be reported to ISMP's national medication error reporting program, and vaccine reactions go to VAERS, run by CDC and FDA. Your pharmacy will also have its own internal error-reporting process.
The Orange Book and therapeutic equivalence
Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book, lists FDA-approved drugs and their therapeutic equivalence (TE) codes.
- "A" codes: FDA considers the product therapeutically equivalent to other pharmaceutically equivalent products. AB is the most common, meaning bioequivalence was shown. Others include AA (conventional dosage forms without bioequivalence problems), AO (injectable oil solutions), AP (injectable aqueous solutions) and AT (topical products).
- "B" codes: FDA does not currently consider the product equivalent. BX means the data are insufficient to decide.
- Numbered codes such as AB1 and AB2 group products that are equivalent to each other but not across groups.
Whether a pharmacist may substitute a generic is decided by state law, which often relies on these codes.
Key takeaways
- The FDCA bans adulterated and misbranded drugs; Durham-Humphrey created the Rx/OTC split.
- An NDC has labeler, product and package segments; 4-4-2, 5-3-2 and 5-4-1 become 5-4-2 for billing.
- FDA's 12-digit (6-4-2) NDC format takes effect March 7, 2033, with a transition period to March 6, 2036.
- Medication Guides must be handed to the patient at dispensing.
- REMS manage serious risks; ETASU can require certified prescribers and pharmacies.
- Class I recalls are the most serious; Class III the least.
- In the Orange Book, "A" means therapeutically equivalent and "B" means not.
Quick check
Q1. Convert the 5-4-1 NDC 54321-0987-6 to the 11-digit 5-4-2 format.
Answer: 54321-0987-06. The one-digit package code gets a leading zero.
Q2. A recalled product is unlikely to harm anyone but has a labeling error. What class of recall is this?
Answer: Class III. It violates FDA rules but is not expected to cause adverse health consequences.
Q3. What does the Orange Book code BX mean?
Answer: FDA lacks enough data to decide therapeutic equivalence, so the product is not considered substitutable on that basis.
Practice these in Pillworks Idle.
Sources
- Federal Register — Revising the National Drug Code Format and Drug Label Barcode Requirements (final rule, 91 FR 10749)
- FDA — Frequently Asked Questions (FAQs) about REMS
- FDA — National Drug Code Format
- FDA — The Over-the-Counter Drug Facts Label
- eCFR — 21 CFR Part 208, Medication Guides for Prescription Drug Products
- FDA — What's in a REMS?
- FDA — Understanding Drug Recalls, What to Know and What to Do
- eCFR — 21 CFR Part 7, Enforcement Policy
- FDA — Reporting Serious Problems to FDA (MedWatch)
- FDA — Preface to the Orange Book